Fmr LLC Ventyx Biosciences, Inc. Transaction History

Fmr LLC

$1.52 Trillion
Q2 2024

A detailed history of Fmr LLC transactions in Ventyx Biosciences, Inc. stock. As of the latest transaction made, Fmr LLC holds 127,032 shares of VTYX stock, worth $284,551. This represents 0.0% of its overall portfolio holdings.

Number of Shares

127,032

Previous 378,621 66.45%

Holding current value

$284,551

Previous $2.08 Million 85.93%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$2.31 - $5.59 $581,170 - $1.41 Million	-251,589 Reduced 66.45%	127,032 $293,000
Q1 2024 May 13, 2024	BUY	$1.9 - $10.13 $587,362 - $3.13 Million	309,138 Added 444.91%	378,621 $2.08 Million
Q4 2023 Feb 13, 2024	SELL	$2.08 - $31.18 $17.9 Million - $268 Million	-8,608,046 Reduced 99.2%	69,483 $171,000
Q3 2023 Nov 13, 2023	BUY	$29.8 - $40.3 $3.7 Million - $5.01 Million	124,298 Added 1.45%	8,677,529 $301 Million
Q2 2023 Aug 11, 2023	BUY	$28.53 - $39.55 $27.1 Million - $37.5 Million	948,890 Added 12.48%	8,553,231 $281 Million
Q1 2023 May 11, 2023	BUY	$29.51 - $46.65 $174 Million - $276 Million	5,909,854 Added 348.77%	7,604,341 $255 Million
Q4 2022 Feb 13, 2023	SELL	$24.16 - $36.38 $4.86 Million - $7.32 Million	-201,325 Reduced 10.62%	1,694,487 $55.6 Million
Q3 2022 Nov 10, 2022	BUY	$12.64 - $38.7 $4.04 Million - $12.4 Million	319,870 Added 20.3%	1,895,812 $65.4 Million
Q2 2022 Aug 12, 2022	BUY	$11.95 - $18.75 $9.07 Million - $14.2 Million	758,903 Added 92.88%	1,575,942 $19.3 Million
Q1 2022 May 13, 2022	BUY	$10.0 - $19.98 $33,670 - $67,272	3,367 Added 0.41%	817,039 $11.1 Million
Q4 2021 Feb 14, 2022	BUY	$14.2 - $23.07 $11.6 Million - $18.8 Million	813,672 New	813,672 $16.2 Million

Others Institutions Holding VTYX

# of Institutions

123

Shares Held

57.5M

Call Options Held

222K

Put Options Held

269K

View Full List

About Ventyx Biosciences, Inc.

Ticker VTYX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,527,200
Market Cap $127M
Description
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis...

More about VTYX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.

Account